85% work on new Khasab Hospital completed
KHASAB: The overall completion rate of the new Khasab Hospital in Musandam Governorate has surpassed 85 per cent. The project is being constructed on a 100,000-square-metre plot, with a built-up area of 36,000 square metres and a total cost exceeding RO 48 million.
With a capacity of 164 beds, the hospital will enhance healthcare services in the governorate.
Eng Yousef bin Yaqoob Amboali, Director-General of Projects and Engineering Services at the Ministry of Health, stated that the new Khasab Hospital in Musandam Governorate is among the key developmental health projects in the governorate and is expected to be completed by the end of this year.
He added that the hospital will include an emergency and accident unit, radiology department, nephrology unit, outpatient clinics, rehabilitation unit, intensive care units, maternity and neonatal care department, day surgery unit, administrative offices, meeting halls, a central sterilisation department and inpatient wards, along with general services.
It is worth noting that once operational, the new Khasab Hospital will provide a range of specialised medical services to meet the treatment needs of citizens and residents, alleviating the burden of travelling to other governorates. - ONA
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Observer
10 hours ago
- Observer
Health ministry unveils ad norms for medicines
To enhance public health safeguards and ensure ethical, accurate representation of pharmaceutical products, the Ministry of Health on Sunday issued Ministerial Resolution No 135/2025, which specifies the conditions and procedures for advertising or promoting medicines. The resolution bans advertising or promoting medicines by any entity other than pharmaceutical companies, local agents, or pharmaceutical consulting offices, with the exception of scientific offices, unless they have obtained prior authorisation from the Drug Safety Centre (DSC). To obtain a licence, the medicine must be officially registered and that the advertisement content be consistent with the internal leaflet and the Summary of Drug Properties (SmPC) specifying the target groups for the advertisement. According to the decision, the advertisement must also adhere to public order and public morals and be free of any content that could harm public health or contain misleading information, exaggerations or insults to other medicines in accordance with the DSC's approved advertising guide. The DSC allows a period not exceeding 60 days to review and decide on the licence application. Failure to respond within this period shall be considered a rejection of the application. In case of missing documents or information, the applicant will be notified and given 30 days to complete the missing information, otherwise, the application will be cancelled. The applicant may submit a new application 30 days after the date of the rejection decision. The licence term is set at 3 months, renewable with the same conditions. The renewal application must be submitted at least 20 days before the licence expires. The decision allows for the submission of a grievance to the Minister of Health within 60 days of the rejection decision. A decision must be made within 30 days. Failure to decide within this period constitutes a rejection of the grievance. The DSC also has the right to suspend the licence if health risks or the drug's ineffectiveness are identified.
Muscat Daily
12 hours ago
- Muscat Daily
MoH tightens rules on promotion, marketing of drugs in Oman
Muscat – Ministry of Health (MoH) has announced new regulations for advertising and promoting medicines aimed at safeguarding public health and ensuring ethical marketing practices in the pharmaceutical sector. Issued by H E Dr Hilal bin Ali al Sabti, Minister of Health, Ministerial Decision No 135/2025 outlines procedures and conditions that pharmaceutical firms, agents and consultants must follow before promoting any medicinal product in Oman. The decision was issued on May 29 and will come into effect from today. Under the new rules, only licensed pharmaceutical companies, authorised local agents and approved pharmaceutical consulting offices can advertise medicines. All advertising must be pre-approved by the Drug Safety Centre. To be eligible for a licence, the product must be registered, and the advertising content must match the approved drug leaflet and summary of product characteristics. It must clearly define the target audience and avoid any wording that could mislead consumers, exaggerate benefits, harm public health or breach public morals. 'The objective is to protect consumers from misleading information and to ensure that advertisements remain factual and within the ethical boundaries of public health,' a ministry official said. Applicants must submit a copy of the advertisement, the drug's registration certificate, proof of fee payment and any other documents requested by the centre. The Drug Safety Centre is mandated to respond within 60 days. No response within that timeframe implies rejection. If an application is found incomplete, the applicant will be given 30 days to address shortcomings. Failure to do so within that period will result in application cancellation. Licences are valid for three months and may be renewed for similar periods. Renewal requests must be submitted at least 20 days before licence expiry and will be assessed under the same terms. Advertisers must include the licence number in all materials and documentation, use only approved formats and obtain prior approval for any change. Advertising prescription-only medicines is restricted to scientific publications or at conferences and professional meetings attended by pharmacists and healthcare workers.
Observer
14 hours ago
- Observer
MoH bans unauthorized medicine commercials
Muscat: The Ministry of Health on Sunday issued Ministerial Resolution No 135/2025, which specifies the conditions and procedures for advertising or promoting medicines. The resolution bans advertising or promoting medicines by any entity other than pharmaceutical companies, local agents, or pharmaceutical consulting offices, with the exception of scientific offices, unless they have obtained prior authorization from the Drug Safety Centre (DSC). In order to obtain a license, the resolution requires that the medicine be officially registered and that the advertisement content be consistent with the internal leaflet and the Summary of Drug Properties (SmPC) specifying the target groups for the advertisement. According to the decision, the advertisement must also adhere to public order and public morals and be free of any content that could harm public health or contain misleading information, exaggerations or insults to other medicines in accordance with the DSC's approved advertising guide. The DSC allows a period not exceeding 60 days to review and decide on the license application. Failure to respond within this period shall be considered a rejection of the application. In case of missing documents or information, the applicant will be notified and given 30 days to complete the missing information, otherwise the application will be cancelled. The applicant may submit a new application 30 days after the date of the rejection decision. The license term is set at 3 months, renewable with the same conditions. The renewal application must be submitted at least 20 days before the license expires. The decision allows for the submission of a grievance to the Minister of Health within 60 days of the rejection decision. A decision must be made within 30 days. Failure to decide within this period constitutes a rejection of the grievance. The DSC also has the right to suspend the license if health risks or the drug's ineffectiveness are identified.
